|1.476 0.016 (1.1%)||11-29 10:11|
|Targets||6-month :||1.91||1-year :||2.17|
|Resists||First :||1.63||Second :||1.86|
|Supports||First :||1.27||Second :||1.06|
|MAs||MA(5) :||1.48||MA(20) :||1.46|
|MA(100) :||2.17||MA(250) :||3.46|
|MACD||MACD :||-0.1||Signal :||-0.1|
|%K %D||K(14,3) :||32.1||D(3) :||33.5|
|52-week||High :||10.94||Low :||1.27|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ IPSC ] has closed below upper band by 29.6%. Bollinger Bands are 23.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
|If tomorrow:||Open lower||Open higher|
|High:||1.48 - 1.49||1.49 - 1.5|
|Low:||1.35 - 1.36||1.36 - 1.37|
|Close:||1.44 - 1.46||1.46 - 1.47|
Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma. Century Therapeutics, Inc. was founded in 2018 and is headquartered in Philadelphia, Pennsylvania.
Thu, 02 Nov 2023
Century Therapeutics to Present Initial Clinical Data Supporting the Potential for a Multi-Dosing Strategy for CAR iNK Enabled by Allo-Evasion™ Edits at the 65th ASH Annual Meeting and Exposition - Yahoo Finance
|Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
|Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
|Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
|Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
|Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
|Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
|Shares Out||0 (M)|
|Shares Float||60 (M)|
|Held by Insiders||2.166e+007 (%)|
|Held by Institutions||37.7 (%)|
|Shares Short||684 (K)|
|Shares Short P.Month||0 (K)|
|EPS Est Next Qtrly||0|
|EPS Est This Year||0|
|EPS Est Next Year||0|
|Book Value (p.s.)||0|
|Profit Margin||0 %|
|Operating Margin||-21 %|
|Return on Assets (ttm)||368.9 %|
|Return on Equity (ttm)||-17.6 %|
|Qtrly Rev. Growth||2.49e+006 %|
|Gross Profit (p.s.)||-124.41|
|Sales Per Share||-62.59|
|Qtrly Earnings Growth||-2.3 %|
|Operating Cash Flow||0 (M)|
|Levered Free Cash Flow||-85 (M)|
|Price to Book value||0|
|Price to Sales||-0.03|
|Price to Cash Flow||0.3|
|Dividend Pay Date||Invalid DateTime.|
|Ex-Dividend Date||Invalid DateTime.|